Eventide Asset Management KYMR Position
Active14-Fund ConvergenceEventide Asset Management trimmed their position in Kymera Therapeutics Inc. (KYMR) in Q4 2025, holding $48.7M worth of shares across 626,430 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
KYMR is a convergence signal: 14 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for KT-621 in 440 days (Jun 30, 2027), making the timing of Eventide's position particularly relevant.
Short interest stands at 14.6% of float with 12.7 days to cover, indicating significant bearish positioning against Eventide's long thesis.
About Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Full company profile →Short Interest
14.6%
12.7 days to cover
Eventide Asset Management KYMR Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 626,430 | -18,160 | $48.7M |
| Q3 2025 | Increased | 644,590 | +81,600 | $36.5M |
| Q2 2025 | Increased | 562,990 | +37,852 | $24.6M |
| Q1 2025 | Increased | 525,138 | +69,410 | $14.4M |
| Q4 2024 | Decreased | 455,728 | -52,174 | $18.3M |
| Q3 2024 | Increased | 507,902 | +45,803 | $24.0M |
| Q2 2024 | Increased | 462,099 | +442,325 | $13.8M |
| Q1 2024 | New | 19,774 | +19,774 | $795K |
Frequently Asked Questions
Does Eventide Asset Management own KYMR?
Yes. As of Q4 2025, Eventide Asset Management holds 626,430 shares of Kymera Therapeutics Inc. (KYMR) valued at $48.7M. This data comes from their SEC 13F filing.
How many hedge funds own KYMR?
14 specialist biotech hedge funds currently hold KYMR, including Baker Bros. Advisors, Avoro Capital Advisors, BVF Partners and 10 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy KYMR?
Eventide Asset Management's position in KYMR was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's KYMR position increasing or decreasing?
Eventide Asset Management trimmed their KYMR position in the most recent quarter, reducing by 18,160 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KYMRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →